2021-01-25 06:30:29

US FDA APPROVED HWGB’S JV PARTNER, EBI TO CONDUCT THE 2ND STAGE OF PHASE 4 CLINICAL TRIAL FOR COVID-19 VACCINATION

KUALA LUMPUR, 25 January 2021 - HWGB Biotech Sdn Bhd (“HWGB Biotech”), a wholly owned subsidiary of Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601), announced that E-MO Biology Inc. (“EBI”) has received approval from the US Food and Drug Administration (“FDA”) for the commencement of stage 2 of the Phase 4 Clinical Trial of SARS-Cov-2 Vaccine. This came after EBI completed the first stage study of Phase 4 clinical trial and successfully submitted their Interim Report of COVID-19 Vaccine study to the FDA on 23 December 2020.
 
With the official approval from the FDA, EBI is allowed to follow up from the first stage of the study and expand their study into a larger group with an additional 275 subjects in United States, which will be stratified by age and ethnicity. The expansion of the study will allow EBI to further evaluate and achieve a more complete characterization of the specimens, utilizing the Western Blot analysis and study the cross-reactivity with the SARS-Cov-2 antigens.
 
Managing Director of EBI, Dr. Xie QiYi, said: “The FDA approval came at a timely manner, with countries all over the globe currently have their hands full with the third wave of the COVID-19 pandemic, the demand for a COVID-19 vaccine that have a better safe and effective profiles is at an unprecedented level. We hope that upon completing the study on the 275 subjects enrolled, we can have a further understanding on the cross-reactivity of SARS-Cov-2 antigens with the Vaccines to gather further evidence for new indication emergency approval”.
 
Please refer to the US Food and Drug Administration website below for more information on EBI’s Phase IV clinical study: https://www.clinicaltrials.gov/ct2/show/NCT04639375



Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare-related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; Trading of wires and cables; and travel agent and tour related services.



HWGB Biotech Sdn Bhd, was incorporated on 18 June 2012 under the Companies Act, 1965 under the former name of HWG Consortium Sdn Bhd and changed to its current name on 22 May 2020. HWGB Biotech is principally involved in the distribution of all kinds of biotechnology products, bioinformatics diagnostic tools, all medical engineering equipment along with software developments and tools as well as to patent all original products and by-products, technologies and software developed or sourced by the company.
 
For more information about HWGB Biotech, follow us on https://hwgbbiotech.com, http://subscription.hwgbbiotech.com, Facebook, LinkedIn, and Telegram to view the latest updates about our company ventures in the healthcare industry.


Please refer to the US Food and Drug Administration website for more information on EBI’s Phase IV clinical study: https://www.clinicaltrials.gov/ct2/show/NCT04639375


Wolrd Health Organization (“WHO”) is an organization that work worldwide to promote health, keep the world safe, and serve the vulnerable. WHO began when their Constitution came into force on 7 April 1948, a date now celebrated every year as World Health Day. They are now more than 7000 people from more than 150 countries working in 150 country offices, in 6 regional offices and at our headquarters in Geneva
For more information about WHO, please refer to the WHO website for more information : https://www.who.int/
 
E-Mo Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Dr. Xie QiYi, who serves as its Managing Director of EBI. He has over 30 years of experience in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on Quality, Regulatory and Clinical Affairs for quality systems.
 

Back